Therefore, we hypothesized that tirazepatide dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists might effectively manage Covid-19-induced hyperglycemia in diabetic and non-diabetic patients. The gene discussed is GIP; the disease is Hyperglycemia.